Rigel Pharmaceuticals’ newly approved breast cancer drug Veppanu got deal clarity as Rigel and its partners finalized commercialization arrangements. Arvinas and Pfizer agreed to find a new partner for the protac medicine after the deal with Rigel created uncertainty months earlier. According to the reports, the arrangement ends months of questions over Veppanu’s financial outlook and distribution path, with rights shifting to Rigel under a commercialization agreement. The episode highlights how quickly commercialization rights for newly approved oncology assets can be renegotiated. For investors and operators, the update reduces visibility risk around revenue capture for a first-of-its-kind therapy in the PROTAC class.